Monthly Archives: February 2020

Emerging Pathogens, Communications

In June 1981 I graduated from law school. One month after that an article appeared in the New York Times with the headline “Rare Cancer Seen in 41 Homosexuals” on page A20. These two events would end up pretty much … Continue reading

Posted in Current Affairs | Leave a comment

The Side Effects of a Coronavirus Epidemic for Pharma

There are a lot of important facts on the FDA’s Web Page set up to provide information about the novel coronoavirus (2019-nCOV) outbreak, now dubbed COVID-19. But there are three sobering statements that stand out: There are no FDA-approved diagnostics … Continue reading

Posted in Current Affairs | Tagged | Comments Off on The Side Effects of a Coronavirus Epidemic for Pharma

FDA Takes A Number of Actions to Enhance the Market for Biosimilars – A Process Not an Event

There is a policy interest in driving the biosimilar market. Among other reasons, increasing the number of generic drugs and biosimilars on the market addresses another policy priority – having an impact on the high cost of medicine. The approval … Continue reading

Posted in Biologics, FDA Policy | Comments Off on FDA Takes A Number of Actions to Enhance the Market for Biosimilars – A Process Not an Event